Literature DB >> 25533034

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.

Lital Shaham1, Elena Vendramini2, Yubin Ge3, Yaron Goren4, Yehudit Birger5, Marloes R Tijssen6, Maureen McNulty7, Ifat Geron2, Omer Schwartzman2, Liat Goldberg5, Stella T Chou8, Holly Pitman3, Mitchell J Weiss8, Shulamit Michaeli9, Benjamin Sredni10, Berthold Göttgens6, John D Crispino7, Jeffrey W Taub11, Shai Izraeli2.   

Abstract

Children with Down syndrome (DS) are at increased risk for acute myeloid leukemias (ML-DS) characterized by mixed megakaryocytic and erythroid phenotype and by acquired mutations in the GATA1 gene resulting in a short GATA1s isoform. The chromosome 21 microRNA (miR)-125b cluster has been previously shown to cooperate with GATA1s in transformation of fetal hematopoietic progenitors. In this study, we report that the expression of miR-486-5p is increased in ML-DS compared with non-DS acute megakaryocytic leukemias (AMKLs). miR-486-5p is regulated by GATA1 and GATA1s that bind to the promoter of its host gene ANK1. miR-486-5p is highly expressed in mouse erythroid precursors and knockdown (KD) in ML-DS cells reduced their erythroid phenotype. Ectopic expression and KD of miR-486-5p in primary fetal liver hematopoietic progenitors demonstrated that miR-486-5p cooperates with Gata1s to enhance their self renewal. Consistent with its activation of AKT, overexpression and KD experiments showed its importance for growth and survival of human leukemic cells. Thus, miR-486-5p cooperates with GATA1s in supporting the growth and survival, and the aberrant erythroid phenotype of the megakaryocytic leukemias of DS.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25533034      PMCID: PMC4335082          DOI: 10.1182/blood-2014-06-581892

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.

Authors:  Jeffrey W Taub; Gina Mundschau; Yubin Ge; Janet M Poulik; Faisal Qureshi; Tanya Jensen; S Jill James; Larry H Matherly; Joshua Wechsler; John D Crispino
Journal:  Blood       Date:  2004-09-01       Impact factor: 22.113

2.  Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.

Authors:  E Ito; M Kasai; Y Hayashi; T Toki; K Arai; S Yokoyama; K Kato; N Tachibana; M Yamamoto; M Yokoyama
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

3.  miR-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose.

Authors:  Yeon Jeong Kim; Soo Hyun Hwang; Sun Young Lee; Keun Koo Shin; Hyun Hwa Cho; Yong Chan Bae; Jin Sup Jung
Journal:  Stem Cells Dev       Date:  2011-11-21       Impact factor: 3.272

4.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486.

Authors:  Eric M Small; Jason R O'Rourke; Viviana Moresi; Lillian B Sutherland; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

Review 5.  Origins of leukaemia in children with Down syndrome.

Authors:  Johann K Hitzler; Alvin Zipursky
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

6.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

7.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

8.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Authors:  Oliver Tunstall-Pedoe; Anindita Roy; Anastasios Karadimitris; Josu de la Fuente; Nicholas M Fisk; Phillip Bennett; Alice Norton; Paresh Vyas; Irene Roberts
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

9.  Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Authors:  N Gefen; V Binder; M Zaliova; Y Linka; M Morrow; A Novosel; L Edry; L Hertzberg; N Shomron; O Williams; J Trka; A Borkhardt; S Izraeli
Journal:  Leukemia       Date:  2009-11-05       Impact factor: 11.528

10.  MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.

Authors:  Valentina Lulli; Paolo Romania; Ornella Morsilli; Paolo Cianciulli; Marco Gabbianelli; Ugo Testa; Alessandro Giuliani; Giovanna Marziali
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more
  36 in total

1.  Down syndrome and microRNAs.

Authors:  Aldina Brás; António S Rodrigues; Bruno Gomes; José Rueff
Journal:  Biomed Rep       Date:  2017-11-17

2.  14q32 and let-7 microRNAs regulate transcriptional networks in fetal and adult human erythroblasts.

Authors:  Samuel Lessard; Mélissa Beaudoin; Stuart H Orkin; Daniel E Bauer; Guillaume Lettre
Journal:  Hum Mol Genet       Date:  2018-04-15       Impact factor: 6.150

3.  Dual Strategies for Argonaute2-Mediated Biogenesis of Erythroid miRNAs Underlie Conserved Requirements for Slicing in Mammals.

Authors:  David Jee; Jr-Shiuan Yang; Sun-Mi Park; D'Juan T Farmer; Jiayu Wen; Timothy Chou; Arthur Chow; Michael T McManus; Michael G Kharas; Eric C Lai
Journal:  Mol Cell       Date:  2018-01-18       Impact factor: 17.970

Review 4.  The biology of pediatric acute megakaryoblastic leukemia.

Authors:  Tanja A Gruber; James R Downing
Journal:  Blood       Date:  2015-07-17       Impact factor: 22.113

5.  MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.

Authors:  Li-Sheng Wang; Ling Li; Liang Li; Su Chu; Keh-Dong Shiang; Min Li; Hui-Yan Sun; Jun Xu; Feng-Jun Xiao; Guihua Sun; John J Rossi; YinWei Ho; Ravi Bhatia
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

6.  A Novel Regulatory Axis, CHD1L-MicroRNA 486-Matrix Metalloproteinase 2, Controls Spermatogonial Stem Cell Properties.

Authors:  Shan-Shan Liu; Eithne Margaret Maguire; Yin-Shan Bai; Li Huang; Yurong Liu; Liping Xu; Iliana Fauzi; Shou-Quan Zhang; Qingzhong Xiao; Ning-Fang Ma
Journal:  Mol Cell Biol       Date:  2019-02-04       Impact factor: 4.272

7.  Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Authors:  Samaneh Sadat Seyyedi; Masoud Soleimani; Marjan Yaghmaie; Monireh Ajami; Mansoureh Ajami; Shahram Pourbeyranvand; Kamran Alimoghaddam; Seyed Mohammad Akrami
Journal:  Tumour Biol       Date:  2015-11-02

8.  ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status.

Authors:  Mathewos Tessema; Christin M Yingling; Maria A Picchi; Guodong Wu; Tyrone Ryba; Yong Lin; Aaron O Bungum; Eric S Edell; Avrum Spira; Steven A Belinsky
Journal:  Cancer Lett       Date:  2017-09-29       Impact factor: 8.679

Review 9.  Down syndrome and leukemia: insights into leukemogenesis and translational targets.

Authors:  Marion K Mateos; Draga Barbaric; Sally-Anne Byatt; Rosemary Sutton; Glenn M Marshall
Journal:  Transl Pediatr       Date:  2015-04

10.  A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.

Authors:  Hernando Lopez-Bertoni; Ivan S Kotchetkov; Nicole Mihelson; Bachchu Lal; Yuan Rui; Heather Ames; Maria Lugo-Fagundo; Hugo Guerrero-Cazares; Alfredo Quiñones-Hinojosa; Jordan J Green; John Laterra
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.